Theralase Technologies Inc. V.TLT

The overall pipeline

[DJDawg]

Thinking on the competition for BCG therapy I remain convinced that the key to longterm success is as follows.

- get BTD to show wider pool of investors that serious drug with good outcomes and FDA respect despite being a tiny tiny company on the tsx venture
- get a financial bump of some kind with the BTD
- use the money to widen the pipeline to show IV rutherrin could do amazing things for typically fatal GBM and advanced NSCLC
- get some kind of thing going with very interesting HSV data to further show the different pipelines

If they can show the world that not a one trick NMIBC pony then they will shoot up as the more viable avenues of sucess = more derisking compared to one drug and one narrow disease type of biotech company.

[Yajne]

Great post DJDawg...total agreement from me

[CancerSlayer]

Agree....would also really like to see the preclinical versatility of this drug begin to clinically shine.  If TLT can demonstrate that our versatile base compound can not only be applied to other indications systemically/intravenously, but also respond to a more simplified/external activation source (i.e. X-ray, other FDA approved compound, nano scintillation, etc.) in a highly unmet

[DeathXray33]

I don't see Rutherrin ever becoming resistant like Cisplatin. Brilliant...

[menoalittle]

Probably because Rutherrin won't be in the same race that Cisplatin is in trying to knockout (or knockdown) carcinoma before it (the Cisplatin) kills you...

[Johnandrose22]

A remarkable CR and jaw dropping durability...with often just one instillation...One!....Data confirmed by an FDA central lab....C'mon...just confirm this and start saving the lives of our family, neighbors and those we will never know.